Do intrauterine devices (IUDs) cause depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IUD and Depression Risk

Levonorgestrel-releasing IUDs (LNG-IUDs) are associated with an increased risk of depression, particularly in adolescents and young women using them as their first hormonal contraceptive, with the highest quality recent evidence showing a 57% increased risk overall and up to 157% increased risk in adolescent users.

Evidence Quality and Strength

The most robust and recent evidence comes from a 2023 Swedish national register-based cohort study of over 703,000 women aged 15-24 1. This large-scale population study found:

  • Overall increased depression risk: 57% (AHR 1.57,95% CI 1.51-1.64)
  • Adolescent users: 157% increased risk (AHR 2.57,95% CI 2.36-2.80)
  • First-time hormonal contraceptive users: 63% increased risk (AHR 1.63,95% CI 1.50-1.78)

A 2023 systematic review corroborates these findings, with 10 studies showing increased depressive symptoms and additional evidence of anxiety and suicidal ideation 2.

Contradictory Evidence

Older evidence from 2018 presents conflicting conclusions:

  • A systematic review of progestin-only methods found minimal association with depression, with 4 out of 5 LNG-IUD studies showing no correlation 3
  • A UK cohort study found associations with anxiety (HR 1.18) and sleep problems (HR 1.22) but focused less on depression 4

The key difference: The 2023 Swedish study is substantially larger, more recent, and specifically examined young women—the highest-risk population.

Critical Risk Factors to Assess

Before prescribing LNG-IUDs, identify high-risk patients:

  1. Age < 25 years (especially adolescents 15-19)
  2. No prior hormonal contraceptive use
  3. Personal or family history of depression/psychiatric disorders
  4. Current depressive symptoms or anxiety

Clinical Algorithm

For adolescents and young women (age 15-24):

  • Conduct psychiatric screening before insertion
  • Counsel explicitly about 2.5-fold increased depression risk
  • Consider copper IUD as alternative (no hormonal effects)
  • If LNG-IUD chosen, schedule follow-up at 3 months for mood assessment

For women ≥25 years with no psychiatric history:

  • Standard counseling about potential mood effects
  • Routine monitoring acceptable

For women with psychiatric history at any age:

  • Strongly consider non-hormonal alternatives (copper IUD)
  • If LNG-IUD used, establish close psychiatric monitoring
  • Counsel about increased risk of anxiety and sleep disturbances 4

Important Caveats

The 2023 Swedish study noted that risk estimates decreased over the study period as LNG-IUDs became more accessible to nulliparous women, suggesting possible confounding by indication—meaning women with pre-existing vulnerabilities may have been selectively prescribed LNG-IUDs 1. A 2026 qualitative study confirms this practice, showing healthcare professionals particularly promote LNG-IUDs to "vulnerable" adolescents 5, which could artificially inflate risk associations.

However, this confounding does not eliminate the clinical concern—it actually reinforces that certain populations are at higher risk and require careful monitoring.

Monitoring and Management

If depression develops after LNG-IUD insertion:

  • Remove device if patient desires (patient autonomy is paramount per 2024 CDC guidelines 6)
  • Offer alternative contraception immediately
  • Refer for psychiatric evaluation if symptoms are moderate-severe
  • Document temporal relationship between insertion and symptom onset

Mandatory counseling points:

  • Depression risk exists, particularly in young users
  • Symptoms may include depressed mood, anxiety, sleep problems, and in rare cases, suicidal ideation 2
  • Patient should contact provider immediately if mood changes occur
  • Removal is always an option

The 2024 CDC guidelines emphasize patient autonomy: if a patient desires removal at any time due to side effects, remove the device and offer counseling on alternatives 6.

Related Questions

Can a recently placed Mirena (levonorgestrel-releasing intrauterine system) cause new-onset brain fog, and what evaluation and management steps are recommended?
Should a levonorgestrel‑releasing Kyleena intrauterine device be removed in a 12‑year‑old female with Down syndrome who developed new‑onset anger outbursts, auditory hallucinations, aggression, and school avoidance one month after insertion, and what further evaluation is recommended?
What estrogen and progesterone levels are considered abnormal in a patient with a Mirena (levonorgestrel) IUD who is experiencing mood, sleep, and anxiety issues?
Which hormone tests should be ordered to evaluate abnormal endocrine levels contributing to anxiety and depression in a woman using a levonorgestrel‑releasing intrauterine device?
Does a hormonal intrauterine device (levonorgestrel-releasing intrauterine system) worsen anxiety?
Should carbidopa be administered before an 18F‑DOPA PET scan when evaluating pancreatic neuroendocrine tumours?
Which topical antibiotic ointment is recommended for treating impetigo?
What precautions should be taken for people around a patient after an 18F‑fluorodeoxyglucose (FDG) PET‑CT scan?
What are the primary female hormones, their functions during the menstrual cycle, and how they change during menopause?
What are the causes and recommended management for a patient with a normal thyroid‑stimulating hormone (TSH) level and elevated free thyroxine (FT4) and free triiodothyronine (FT3)?
At what estimated glomerular filtration rate (eGFR) should keto‑analogue supplementation be initiated in chronic kidney disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.